Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme
Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic gonadotrophin (hCG), and unconjugated oestriol (uE3) was made available to five health districts in East Anglia, with a total pop...
Gespeichert in:
| Veröffentlicht in: | Prenatal diagnosis 1994-05, Vol.14 (5), p.391-402 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 402 |
|---|---|
| container_issue | 5 |
| container_start_page | 391 |
| container_title | Prenatal diagnosis |
| container_volume | 14 |
| creator | Goodburn, S. F. Yates, J. R. W. Raggatt, P. R. Carr, C. Ferguson-Smith, M. E. Kershaw, A. J. Milton, P. J. D. Ferguson-Smith, M. A. |
| description | Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic gonadotrophin (hCG), and unconjugated oestriol (uE3) was made available to five health districts in East Anglia, with a total population of 1·2 million. Amniocentesis was offered when the risk of Down's syndrome at term was 1:200 or greater. 25359 singleton pregnancies were screened, representing an uptake of 77 per cent. The recall rate for the 24 per cent of women who had not had a dating scan prior to the test was 9·4 per cent compared with 3·9 per cent for those who had been scanned (P |
| doi_str_mv | 10.1002/pd.1970140509 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76708832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76708832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3499-dbde970114e26d462053674c7646b047790f7594f6347e85a2e9b5c8150f5d2d3</originalsourceid><addsrcrecordid>eNqFkktv1DAUhS0EKsPAkiWSF4gVKXbiR8yuGtoCKg-J19Ly2DeZlMQOdiLaX8NfxaOJBrGBzfXifj7n-F4j9JiSU0pI-WJ0p1RJQhnhRN1BK0qULEhZVnfRiuROUdWc3kcPUrrOeF0qeYJOJC-pEmyFfn0CG7wrptgNkCaIeDC5etPjBHEecLIRwHe-xXPaV9OPO1M0MIUxhgk6_xzv5sF4bHchdsF3FrfBGxemGMbdvm28w7PPLtdzm7UdDtkoo_1LfH4zQuzAW8ChwQZHaLNE9s7abTTDAA_Rvcb0CR4t5xp9uTj_vHldXH24fLM5uypsxZQq3NbBfgiUQSkcEyXhlZDMSsHEljApFWkkV6wRFZNQc1OC2nJbU04a7kpXrdGzg252_jHngHrokoW-Nx7CnLQUktR1Vf4XpEJUebo8g8UBtDGkFKHRY56xibeaEr3fnB6d_rO5zD9ZhOftAO5IL6vK_adL3yRr-iYab7t0xBhRlOeEayQP2M-uh9t_e-qPr_4KsATu8j-4Od408bsWMr9Jf3t_qd--Ixt-8XWjefUbfNrCXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16637525</pqid></control><display><type>article</type><title>Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Goodburn, S. F. ; Yates, J. R. W. ; Raggatt, P. R. ; Carr, C. ; Ferguson-Smith, M. E. ; Kershaw, A. J. ; Milton, P. J. D. ; Ferguson-Smith, M. A.</creator><creatorcontrib>Goodburn, S. F. ; Yates, J. R. W. ; Raggatt, P. R. ; Carr, C. ; Ferguson-Smith, M. E. ; Kershaw, A. J. ; Milton, P. J. D. ; Ferguson-Smith, M. A.</creatorcontrib><description>Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic gonadotrophin (hCG), and unconjugated oestriol (uE3) was made available to five health districts in East Anglia, with a total population of 1·2 million. Amniocentesis was offered when the risk of Down's syndrome at term was 1:200 or greater. 25359 singleton pregnancies were screened, representing an uptake of 77 per cent. The recall rate for the 24 per cent of women who had not had a dating scan prior to the test was 9·4 per cent compared with 3·9 per cent for those who had been scanned (P<0·0005). Seventy‐five per cent (36/48) of Down's syndrome pregnancies were detected for a false‐positive rate of 4·0 per cent. Twenty‐five out of 36 of detected Down's syndrome pregnancies were dated by scan prior to sampling, and in the 11 remaining cases, the dates were confirmed by scan after a high‐risk result was obtained. The exclusion of uE3 from the screening protocol would have reduced the detection rate to 52 per cent (25/48) for the same false‐positive rate. Eighty‐five per cent of women identified at high risk accepted the offer of an amniocentesis. Other fetal abnormalities detected were trisomy 18 (3), trisomy 13 (2), 45,X (6), 69,XXX (5), other chromosome abnormalities (9), open neural tube defects (26), hydrocephalus (7), abdominal wall defects (4), and steroid sulphatase deficiency (6).</description><identifier>ISSN: 0197-3851</identifier><identifier>EISSN: 1097-0223</identifier><identifier>DOI: 10.1002/pd.1970140509</identifier><identifier>PMID: 7521964</identifier><identifier>CODEN: PRDIDM</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; alpha -fetoprotein ; alpha-Fetoproteins - analysis ; amniocentesis ; Biological and medical sciences ; chorionic gonadotropin ; Chorionic Gonadotropin - blood ; Chromosome Aberrations ; Down Syndrome - blood ; Down Syndrome - diagnosis ; Down Syndrome - epidemiology ; Down's syndrome ; estriol ; Estriol - blood ; False Positive Reactions ; Female ; Gynecology. Andrology. Obstetrics ; human chorionic gonadotrophin ; Humans ; man ; Management. Prenatal diagnosis ; Maternal serum screening ; Medical sciences ; Pregnancy ; Pregnancy Trimester, Second ; Pregnancy. Fetus. Placenta ; Prenatal Diagnosis ; serum ; unconjugated oestriol</subject><ispartof>Prenatal diagnosis, 1994-05, Vol.14 (5), p.391-402</ispartof><rights>Copyright © 1994 John Wiley & Sons, Ltd.</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3499-dbde970114e26d462053674c7646b047790f7594f6347e85a2e9b5c8150f5d2d3</citedby><cites>FETCH-LOGICAL-c3499-dbde970114e26d462053674c7646b047790f7594f6347e85a2e9b5c8150f5d2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpd.1970140509$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpd.1970140509$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4091588$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7521964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goodburn, S. F.</creatorcontrib><creatorcontrib>Yates, J. R. W.</creatorcontrib><creatorcontrib>Raggatt, P. R.</creatorcontrib><creatorcontrib>Carr, C.</creatorcontrib><creatorcontrib>Ferguson-Smith, M. E.</creatorcontrib><creatorcontrib>Kershaw, A. J.</creatorcontrib><creatorcontrib>Milton, P. J. D.</creatorcontrib><creatorcontrib>Ferguson-Smith, M. A.</creatorcontrib><title>Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme</title><title>Prenatal diagnosis</title><addtitle>Prenat. Diagn</addtitle><description>Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic gonadotrophin (hCG), and unconjugated oestriol (uE3) was made available to five health districts in East Anglia, with a total population of 1·2 million. Amniocentesis was offered when the risk of Down's syndrome at term was 1:200 or greater. 25359 singleton pregnancies were screened, representing an uptake of 77 per cent. The recall rate for the 24 per cent of women who had not had a dating scan prior to the test was 9·4 per cent compared with 3·9 per cent for those who had been scanned (P<0·0005). Seventy‐five per cent (36/48) of Down's syndrome pregnancies were detected for a false‐positive rate of 4·0 per cent. Twenty‐five out of 36 of detected Down's syndrome pregnancies were dated by scan prior to sampling, and in the 11 remaining cases, the dates were confirmed by scan after a high‐risk result was obtained. The exclusion of uE3 from the screening protocol would have reduced the detection rate to 52 per cent (25/48) for the same false‐positive rate. Eighty‐five per cent of women identified at high risk accepted the offer of an amniocentesis. Other fetal abnormalities detected were trisomy 18 (3), trisomy 13 (2), 45,X (6), 69,XXX (5), other chromosome abnormalities (9), open neural tube defects (26), hydrocephalus (7), abdominal wall defects (4), and steroid sulphatase deficiency (6).</description><subject>Adult</subject><subject>alpha -fetoprotein</subject><subject>alpha-Fetoproteins - analysis</subject><subject>amniocentesis</subject><subject>Biological and medical sciences</subject><subject>chorionic gonadotropin</subject><subject>Chorionic Gonadotropin - blood</subject><subject>Chromosome Aberrations</subject><subject>Down Syndrome - blood</subject><subject>Down Syndrome - diagnosis</subject><subject>Down Syndrome - epidemiology</subject><subject>Down's syndrome</subject><subject>estriol</subject><subject>Estriol - blood</subject><subject>False Positive Reactions</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>human chorionic gonadotrophin</subject><subject>Humans</subject><subject>man</subject><subject>Management. Prenatal diagnosis</subject><subject>Maternal serum screening</subject><subject>Medical sciences</subject><subject>Pregnancy</subject><subject>Pregnancy Trimester, Second</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>Prenatal Diagnosis</subject><subject>serum</subject><subject>unconjugated oestriol</subject><issn>0197-3851</issn><issn>1097-0223</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkktv1DAUhS0EKsPAkiWSF4gVKXbiR8yuGtoCKg-J19Ly2DeZlMQOdiLaX8NfxaOJBrGBzfXifj7n-F4j9JiSU0pI-WJ0p1RJQhnhRN1BK0qULEhZVnfRiuROUdWc3kcPUrrOeF0qeYJOJC-pEmyFfn0CG7wrptgNkCaIeDC5etPjBHEecLIRwHe-xXPaV9OPO1M0MIUxhgk6_xzv5sF4bHchdsF3FrfBGxemGMbdvm28w7PPLtdzm7UdDtkoo_1LfH4zQuzAW8ChwQZHaLNE9s7abTTDAA_Rvcb0CR4t5xp9uTj_vHldXH24fLM5uypsxZQq3NbBfgiUQSkcEyXhlZDMSsHEljApFWkkV6wRFZNQc1OC2nJbU04a7kpXrdGzg252_jHngHrokoW-Nx7CnLQUktR1Vf4XpEJUebo8g8UBtDGkFKHRY56xibeaEr3fnB6d_rO5zD9ZhOftAO5IL6vK_adL3yRr-iYab7t0xBhRlOeEayQP2M-uh9t_e-qPr_4KsATu8j-4Od408bsWMr9Jf3t_qd--Ixt-8XWjefUbfNrCXg</recordid><startdate>199405</startdate><enddate>199405</enddate><creator>Goodburn, S. F.</creator><creator>Yates, J. R. W.</creator><creator>Raggatt, P. R.</creator><creator>Carr, C.</creator><creator>Ferguson-Smith, M. E.</creator><creator>Kershaw, A. J.</creator><creator>Milton, P. J. D.</creator><creator>Ferguson-Smith, M. A.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T3</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>199405</creationdate><title>Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme</title><author>Goodburn, S. F. ; Yates, J. R. W. ; Raggatt, P. R. ; Carr, C. ; Ferguson-Smith, M. E. ; Kershaw, A. J. ; Milton, P. J. D. ; Ferguson-Smith, M. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3499-dbde970114e26d462053674c7646b047790f7594f6347e85a2e9b5c8150f5d2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>alpha -fetoprotein</topic><topic>alpha-Fetoproteins - analysis</topic><topic>amniocentesis</topic><topic>Biological and medical sciences</topic><topic>chorionic gonadotropin</topic><topic>Chorionic Gonadotropin - blood</topic><topic>Chromosome Aberrations</topic><topic>Down Syndrome - blood</topic><topic>Down Syndrome - diagnosis</topic><topic>Down Syndrome - epidemiology</topic><topic>Down's syndrome</topic><topic>estriol</topic><topic>Estriol - blood</topic><topic>False Positive Reactions</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>human chorionic gonadotrophin</topic><topic>Humans</topic><topic>man</topic><topic>Management. Prenatal diagnosis</topic><topic>Maternal serum screening</topic><topic>Medical sciences</topic><topic>Pregnancy</topic><topic>Pregnancy Trimester, Second</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>Prenatal Diagnosis</topic><topic>serum</topic><topic>unconjugated oestriol</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goodburn, S. F.</creatorcontrib><creatorcontrib>Yates, J. R. W.</creatorcontrib><creatorcontrib>Raggatt, P. R.</creatorcontrib><creatorcontrib>Carr, C.</creatorcontrib><creatorcontrib>Ferguson-Smith, M. E.</creatorcontrib><creatorcontrib>Kershaw, A. J.</creatorcontrib><creatorcontrib>Milton, P. J. D.</creatorcontrib><creatorcontrib>Ferguson-Smith, M. A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Human Genome Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Prenatal diagnosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goodburn, S. F.</au><au>Yates, J. R. W.</au><au>Raggatt, P. R.</au><au>Carr, C.</au><au>Ferguson-Smith, M. E.</au><au>Kershaw, A. J.</au><au>Milton, P. J. D.</au><au>Ferguson-Smith, M. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme</atitle><jtitle>Prenatal diagnosis</jtitle><addtitle>Prenat. Diagn</addtitle><date>1994-05</date><risdate>1994</risdate><volume>14</volume><issue>5</issue><spage>391</spage><epage>402</epage><pages>391-402</pages><issn>0197-3851</issn><eissn>1097-0223</eissn><coden>PRDIDM</coden><abstract>Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic gonadotrophin (hCG), and unconjugated oestriol (uE3) was made available to five health districts in East Anglia, with a total population of 1·2 million. Amniocentesis was offered when the risk of Down's syndrome at term was 1:200 or greater. 25359 singleton pregnancies were screened, representing an uptake of 77 per cent. The recall rate for the 24 per cent of women who had not had a dating scan prior to the test was 9·4 per cent compared with 3·9 per cent for those who had been scanned (P<0·0005). Seventy‐five per cent (36/48) of Down's syndrome pregnancies were detected for a false‐positive rate of 4·0 per cent. Twenty‐five out of 36 of detected Down's syndrome pregnancies were dated by scan prior to sampling, and in the 11 remaining cases, the dates were confirmed by scan after a high‐risk result was obtained. The exclusion of uE3 from the screening protocol would have reduced the detection rate to 52 per cent (25/48) for the same false‐positive rate. Eighty‐five per cent of women identified at high risk accepted the offer of an amniocentesis. Other fetal abnormalities detected were trisomy 18 (3), trisomy 13 (2), 45,X (6), 69,XXX (5), other chromosome abnormalities (9), open neural tube defects (26), hydrocephalus (7), abdominal wall defects (4), and steroid sulphatase deficiency (6).</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>7521964</pmid><doi>10.1002/pd.1970140509</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0197-3851 |
| ispartof | Prenatal diagnosis, 1994-05, Vol.14 (5), p.391-402 |
| issn | 0197-3851 1097-0223 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76708832 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult alpha -fetoprotein alpha-Fetoproteins - analysis amniocentesis Biological and medical sciences chorionic gonadotropin Chorionic Gonadotropin - blood Chromosome Aberrations Down Syndrome - blood Down Syndrome - diagnosis Down Syndrome - epidemiology Down's syndrome estriol Estriol - blood False Positive Reactions Female Gynecology. Andrology. Obstetrics human chorionic gonadotrophin Humans man Management. Prenatal diagnosis Maternal serum screening Medical sciences Pregnancy Pregnancy Trimester, Second Pregnancy. Fetus. Placenta Prenatal Diagnosis serum unconjugated oestriol |
| title | Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A08%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second-trimester%20maternal%20serum%20screening%20using%20alpha-fetoprotein,%20human%20chorionic%20gonadotrophin,%20and%20unconjugated%20oestriol:%20Experience%20of%20a%20regional%20programme&rft.jtitle=Prenatal%20diagnosis&rft.au=Goodburn,%20S.%20F.&rft.date=1994-05&rft.volume=14&rft.issue=5&rft.spage=391&rft.epage=402&rft.pages=391-402&rft.issn=0197-3851&rft.eissn=1097-0223&rft.coden=PRDIDM&rft_id=info:doi/10.1002/pd.1970140509&rft_dat=%3Cproquest_cross%3E76708832%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16637525&rft_id=info:pmid/7521964&rfr_iscdi=true |